← SCREEN  |  EPAM (anchor)  |  GLOB  |  BAH

Cognizant Technology Solutions (CTSH) — short thesis deep-dive stub

Largest US-listed pure-play IT services firm. $21.1B FY25 rev, ~351,600 FTE (~70% India/Philippines/LatAm). US GAAP reporter; ~75% NA revenue. Role: co-anchor satellite alongside EPAM. Grade: B. Generated 2026-04-19.
📡 Next catalyst: Q1 FY26 earnings — Wed Apr 29, 2026
BFSI re-acceleration narrative is the key tell. Stock has been de-rated; print sets the tape for the anchor thesis.
 •  IR home ↗  •  Quarterly results ↗  •  Events & webcasts ↗  •  Press releases ↗
Short thesis (bottom line): CTSH's revenue is priced per seat-month of mid-level offshore engineer. Staff-augmentation app-dev hours — the plurality of revenue — are the exact work Devin-class agents, Copilot Workspace, and enterprise AI platforms most credibly substitute. New CEO (Ravi Kumar, ex-Infosys, Jan 2023) is executing an "AI Builder" re-positioning but the business model is structurally exposed. Most direct institutional target for the AI-eats-IT-services thesis.

Edge vs priced-in: Fwd P/E 10.9x, EV/EBITDA 7.5x, stock near 52-wk low $57.39 (vs high $87.03). Already de-rated. UBS/Baird/Citi PT cuts in April. But fortress balance sheet, active buyback, and activist-targeted status (Starboard 2022-23) create a PE-buyout floor.

Counter-signal: BFSI segment (~29% of rev) grew +9% YoY CC in Q4 25 — "highest annual level since 2016." Management attributes to "return of discretionary growth work alongside AI initiatives." This is a serious headwind for the AI-deflation short. Anti-thesis tape confirmed by ACN/INFY.
Why NOT to replace EPAM: The EPAM edge is in the fundamentals (the earnings narrative the short thesis rests on). The CTSH edge is in tradability (liquidity, options access). Anchor's job is to carry the thesis, not just the flows. CTSH = co-anchor satellite, not replacement.

Key metrics

$61.30Spot $29.6BMarket cap 10.9xFwd P/E 7.5xEV/EBITDA $21.1BFY25 rev ~351.6kFTE +9%BFSI Q4 CC +4.9%Rev growth YoY

Segment breakdown (FY25, $21.108B)

SegmentFY25 Rev ($M)ShareQ4 CC growth
Financial Services (BFSI)6,17329.2%+9% YoY CC (accelerating)
Health Sciences6,34730.1%flat-to-modest, "resilient"
Products & Resources5,28525.0%+960 bps from Belcan inorganic
Communications, Media & Tech3,30315.7%organic, large-deal wins

Trade construction (Option B — recommended satellite)

Decision: B (satellite / co-anchor, NOT replacement for EPAM). Maintain EPAM at current weight. Add CTSH at ~50% of EPAM weight.
• Primary: Jan 16, 2027 $55 put × 3 contracts (~$1,500 premium)
• LEAPS starter: Jan 2028 $50 put × 1 contract (~$600, mid $6)
• Total commit: ~$2,100 = ~0.7% of $300k book (satellite scale)
• Net IT-services exposure: 3% (EPAM alone) → 4.5-5% (EPAM + CTSH)
• Upgrade triggers (B → A co-anchor): (i) Apr 29 print confirms BFSI slowing, (ii) Q2 26 (late-July) shows headcount turning, (iii) ACN or INFY tape goes visibly negative first

Kill-switches (any one triggers exit within 5 trading days)

  1. Q1 26 print Apr 29 beats top of guide + raises FY26 guide → thesis invalidated; exit.
  2. BFSI segment grows >+10% CC in Q1 26 → re-acceleration confirmed; exit.
  3. Headcount prints up >+5% YoY in Q1 26 → demand-softness thesis invalidated; reduce 50%.
  4. Stock closes >$72 (20% above entry) on positive catalyst → exit.
  5. Announced PE / strategic approach → exit immediately (catastrophic for short put).
Full deep-dive: This is a stub. The complete 323-line analysis (business breakdown, cost structure, AI exposure mapping, balance sheet, valuation vs INFY/WIT/TCS/ACN/EPAM, full transcript quotes from Q4 25 + Q3 25 calls, catalyst calendar, LEAPS liquidity table, EPAM head-to-head, kill-switch detail) is in universe_expansion/CTSH_deep_dive.md.